SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 695.46+2.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CuttingEdge Bio who wrote (2771)10/29/2019 4:25:10 PM
From: Miljenko Zuanic   of 3557
 
Chemo generate synergy by *antigen generating*, the same way avastin with ADCC, so they do help/bust aPD1 response. Idea with aCTLA4 is break-up resistance to aPD1, so low dose and modified regime (RCC or melanoma) do help pusk *durable* response in right direction. My guess is up to right regime to do the same for NSCLC, where *aggressive* regime (for rapidly progressive cancer) are needed to generate durable clinical benefit.

IF REGN do not see any light with aCTLA4, kill the candidate! None will abject!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News